Sector News

Wondering how Teva found room to cut $3B? Look at its past mistakes, CEO says

January 10, 2018
Life sciences

Since new CEO Kåre Schultz rolled out Teva’s $3 billion cost-cutting plan a few weeks back, “some have asked me, ‘how on earth is this possible?’” he said Monday at the J.P. Morgan Healthcare Conference.

One word: structure.

The company has had its generics, specialty meds and global staff functions—including human resources and communications—siloed, he said. And besides creating a situation where “very few people have had a good grip on the operating profit and the P&L,” that structure also resulted in a larger workforce than Schultz thinks was necessary.

Merging the three units into one “takes out two-thirds of management in some cases and simplifies the whole operation,” he said.

The fact that Teva has grown through acquisitions hasn’t helped, either. “Unless you’re very motivated to squeeze out costs and create synergies, you don’t necessarily consolidate everything,” Schultz noted, adding that it can be “very suboptimal from a cost-efficiency point of view as opposed to if you grow organically.”

Take manufacturing, for example: Teva probably needs just 2 to 4 API sites and between 8 and 12 functional manufacturing sites, he said. But today, the company has 80 sites.

All of that’s about to change, though, as Teva pushes forward with a cost-cutting plan that’s set to claim 14,000 jobs. While the plan has sparked nationwide labor protests in the company’s home country of Israel, Schultz reassured investors that it was “very firm” and would “definitely happen, so you don’t need to worry about that part of it.”

And there are other changes on the way, too—such as an increased focus on operating profit.

“Teva used to focus on maximizing revenue in the generics business believing that if you just maximize revenue, everything will fall into place and you’ll get great profitability and so on,” Schultz said.

But “that doesn’t really work from my point of view,” he said. “You always need to maximize operating profit.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach